

# CITATION REPORT

List of articles citing

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

DOI: 10.1186/s12885-019-6175-2  
BMC Cancer, 2019, 19, 1025.

**Source:** <https://exaly.com/paper-pdf/72380683/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 1330-1360	3.5	31
6	METTL3 induces PLX4032 resistance in melanoma by promoting mA-dependent EGFR translation. <i>Cancer Letters</i> , <b>2021</b> , 522, 44-56	9.9	3
5	Analysis of alternative mRNA splicing in vemurafenib-resistant melanoma cells.		1
4	Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells. <i>Biomolecules</i> , <b>2022</b> , 12, 993	5.9	
3	A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer. <b>2022</b> , 14, 4291		0
2	AI + precision medicine. <b>2023</b> , 69-98		0
1	MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer. <b>2023</b> , 559, 216116		0